

Start Me Up: How Can Surrounding Gangliosides Affect Sodium-Potassium ATPase Activity and Steer towards Pathological Ion Imbalance in Neurons?

Puljko, Borna; Stojanović, Mario; Ilić, Katarina; Kalanj-Bognar, Svjetlana; Mlinac-Jerković, Kristina

Source / Izvornik: **Biomedicines**, 2022, 10

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.3390/biomedicines10071518>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:685787>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-10-20**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)





Review

Start Me Up: How Can Surrounding Gangliosides Affect Sodium-Potassium ATPase Activity and Steer towards Pathological Ion Imbalance in Neurons?

Borna Puljko ¹, Mario Stojanović ¹, Katarina Ilic ^{1,2}, Svjetlana Kalanj-Bognar ¹ and Kristina Mlinac-Jerkovic ^{1,*}

¹ Croatian Institute for Brain Research, School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia; borna.puljko@mef.hr (B.P.); mario.stojanovic@mef.hr (M.S.); katarina.ilic@kcl.ac.uk (K.I.); svjetlana.kalanj.bognar@mef.hr (S.K.-B.)

² BRAIN Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IOPPN), King's College London, London SE5 9NU, UK

* Correspondence: kristina.mlinac.jerkovic@mef.hr



Citation: Puljko, B.; Stojanović, M.; Ilic, K.; Kalanj-Bognar, S.; Mlinac-Jerkovic, K. Start Me Up: How Can Surrounding Gangliosides Affect Sodium-Potassium ATPase Activity and Steer towards Pathological Ion Imbalance in Neurons? *Biomedicines* **2022**, *10*, 1518. <https://doi.org/10.3390/biomedicines10071518>

Academic Editors: Anca Sima, Loredan Stefan Niculescu, Camelia Sorina Stancu, Maria I. Dorobantu and Marco Segatto

Received: 27 April 2022

Accepted: 24 June 2022

Published: 27 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Gangliosides, amphiphilic glycosphingolipids, tend to associate laterally with other membrane constituents and undergo extensive interactions with membrane proteins in *cis* or *trans* configurations. Studies of human diseases resulting from mutations in the ganglioside biosynthesis pathway and research on transgenic mice with the same mutations implicate gangliosides in the pathogenesis of epilepsy. Gangliosides are reported to affect the activity of the Na⁺/K⁺-ATPase, the ubiquitously expressed plasma membrane pump responsible for the stabilization of the resting membrane potential by hyperpolarization, firing up the action potential and ion homeostasis. Impaired Na⁺/K⁺-ATPase activity has also been hypothesized to cause seizures by several mechanisms. In this review we present different epileptic phenotypes that are caused by impaired activity of Na⁺/K⁺-ATPase or changed membrane ganglioside composition. We further discuss how gangliosides may influence Na⁺/K⁺-ATPase activity by acting as lipid sorting machinery providing the optimal stage for Na⁺/K⁺-ATPase function. By establishing a distinct lipid environment, together with other membrane lipids, gangliosides possibly modulate Na⁺/K⁺-ATPase activity and aid in “starting up” and “turning off” this vital pump. Therefore, structural changes of neuronal membranes caused by altered ganglioside composition can be a contributing factor leading to aberrant Na⁺/K⁺-ATPase activity and ion imbalance priming neurons for pathological firing.

Keywords: glycosphingolipids; lipid rafts; membrane microdomains; neuronal ion homeostasis; GM1; Na⁺/K⁺-ATPase; sodium-potassium pump; epilepsy

1. Membrane Dynamics and Lipid-Protein Interplay

The plasma membrane is a highly complex and dynamic structure, organized as an asymmetric lipid bilayer containing various (macro)molecules including phospholipids, cholesterol, glycolipids, sphingolipids, and proteins. Membrane dynamics depend on membrane composition and the formation of liquid-ordered and disordered phases which accommodate specific proteins [1,2]. Proteins and lipids, as major constituents of biological membranes, undergo a number of interactions which underlie crucial phenomena and cellular functions such as preservation of membrane properties, signal transduction and molecular exchange of the cell with its environment [3]. Proper functions of proteins, the working part of the membrane assemblage, are intertwined with and influenced by the specific lipid environment and topology of the membrane microdomains. Both protein structures and functions are known to be regulated by specific interactions with their neighboring lipids [4–6], yet exact mechanisms are still poorly understood; hence, more detailed studies are required [7]. Recently, with the advances in structural biology, membrane

proteins got their spotlight under the cryo-electron microscope and more innately bound lipids arose in structural models as crucial players in the regulation of membrane protein distribution and functions [8]. This opened the door for a detailed investigation in the field of protein-lipid interplay and allowed computational approaches to this matter. Molecular dynamics (MD) simulations have been used to study the protein-lipid interplay [9,10], by allowing membrane protein structures to be computationally assembled into lipid bilayers and their interactions characterized [11]. This approach can also take into consideration the glycan moieties of both protein and lipid constituents of the membrane. Amongst proteins readily investigated by these approaches are ion channels [12–14] and outer membrane proteins [15,16]. MD simulations have characterized experimentally observed interactions between cholesterol and G-protein coupled receptors (GPCRs) [10]. In addition, MD simulations have also been used to identify binding sites for phosphatidylinositol 4,5-bisphosphate (PIP₂) in ion channels, transporters and receptor proteins [17]. MD became the method of choice for unraveling nanoscale phenomena since it yields great accuracy in understanding the properties of lipid membranes and lipid–protein interactions that can describe biological membranes in a relatively realistic manner [18]. Nevertheless, although computational models have provided important insight into the organization of plasma membrane and protein-lipid interactions, and interesting and relevant work has been performed on artificial membranes [19–21], they do not necessarily give an entirely accurate insight into protein-lipid interactions as they happen in membranes of living organisms.

Studying the physiological effect of lipids on membrane proteins and enzymes in actual “real” membranes, albeit challenging, is indispensable for thorough understanding of all membrane-related phenomena. The innovations in imaging techniques allow for detailed and accurate visualization of membrane dynamics in membrane systems and live cells [22–24]. For example, such visualisation showed that ganglioside GT1b together with synaptotagmin 1/2 serves as a receptor component for botulinum neurotoxin type B (BoNT/B) [25].

2. Gangliosides

2.1. Short Overview of Gangliosides

Glycolipids are amphiphilic molecules composed of hydrophobic alkyl tails, which anchor them to the phospholipid bilayer, and a hydrophilic oligosaccharide headgroup. Numerous species of glycolipids exist, differing in oligosaccharide headgroups, lipid backbones, and alkyl tails [26]. Gangliosides are glycosphingolipids consisting of a ceramide tail attached by a glycosidic linkage to a glycan headgroup with one or more sialic acid residues [27]. They are harbored in the outer leaflet of the membrane where their ceramide moieties partition them laterally into lipid rafts—spatially and temporally dynamic membrane microdomains that contain other sphingolipids, phospholipids, cholesterol, and specific proteins [28]. Several hundreds of ganglioside structures have been characterized based on differences in oligosaccharide chains or the fatty acids linked to the ceramide [29]. The total mass and specific ganglioside composition vary significantly between different cell types and tissues. The human brain contains up to 30-fold more gangliosides than other tissues [27], and they provide a significant part of neuronal surface glycans [30]. Four gangliosides—GM1, GD1a, GD1b, and GT1b—are the most abundant in the mammalian brain [31], with extraordinary regional pattern differences [32]. Gangliosides are synthesized stepwise by a vast number of glycosyltransferases in a complex biosynthetic pathway in the Golgi apparatus from where they are trafficked to the plasma membrane [33,34]. They play a crucial role in various physiological processes including brain development, aging, and neurodegeneration by modulating the cell signal transduction pathways, neuronal differentiation, and structures and functions of membrane proteins [26,35]. The functions of gangliosides in the central nervous system can be revealed by the physiological manifestations of genetic mutations in the ganglioside biosynthetic pathway, observed both from studies of rare human diseases resulting from mutations in the ganglioside biosynthesis pathway and transgenic mouse models with impaired synthesis of gangliosides [36,37].

Analogously to lipid-protein interactions, a general feature of gangliosides is their capability to associate laterally with other molecules within the membrane [38]. The hydrogen-bonding ability of their headgroups results in extensive *cis*- or *trans*- interactions with membrane proteins [31,39]. *Cis*-interactions with membrane proteins in the same membrane modulate their localization within membrane subdomains, e.g., lipid rafts [40–42]. Being lipid raft constituents, gangliosides are implicated in regulation of the activity of plasma membrane proteins, including protein tyrosine kinases. Many receptor tyrosine kinases, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and insulin receptor (IR) are localized in lipid rafts, and their dimerization and/or recruitment of signaling partners are affected by gangliosides, thus influencing their respective signaling pathways [40,43–45]. Furthermore, there is evidence on regulatory effects of gangliosides on the function of the GluR2-AMPA receptor (AMPA), crucial for learning and memory formation process [46]. Ganglioside GM1 was also shown to promote axonal growth by bringing together the TrkA and laminin-1/beta1 integrin complexes [47]. Ganglioside biology and physiological functions, particularly in mammalian brain, have been exceptionally well described by Schnaar et al. [31,36]. Undoubtedly, a large body of data supports the notion of gangliosides as essential molecular signatures of cell surfaces, where they function as ligands for various glycan-binding proteins, such as bacterial toxins, cell adhesion molecules and receptor kinases [25,40,43–47]. Despite comprehensive studies of ganglioside-protein interactions, the nature of these interactions is still not fully investigated and many details await elucidation.

2.2. Potential Role of Gangliosides in the Molecular Pathogenesis of Seizures

Epilepsy is a disease of the central nervous system characterized by pathological neuronal activity. Neuronal hyperactivity leads to abnormal, extensive, and uncontrolled symptomatology which can be presented as motor, sensory, cognitive, or autonomic disturbances. Pathological firing of neurons can have generalized onset, or focal onset with a possibility for bilateral tonic-clonic propagation or of the unknown onset [48]. There are many different causes of epileptic seizures [49], but the main feature of the seizure generation is either abnormal rhythmic and tonic excitation of neurons, or the aberrant interplay between inhibitory and excitatory neurons and altered membrane conductance [50]. Interestingly, several studies have associated mutations in ganglioside biosynthetic genes with epilepsy in humans. Mutations in the *ST3GAL5* gene, encoding for the GM3-synthase, result in an early-onset seizure disorder, also known as the salt and pepper syndrome, characterized by motor and cognitive disturbances [51]. GM3-synthase catalyzes the first step in the production of gangliosides by transferring a sialic acid residue to lactosylceramide to form GM3; thus, loss of its catalytic activity prevents the formation of GM3 and other complex gangliosides. Contrary to observed effects of altered GM3 synthase activity in humans, no neurological deficits but altered insulin responsiveness was found in a comparison study on the *St3gal5-null* mice [52], while mice expressing only the GM3 ganglioside exhibit lethal audiogenic seizures [53]. Furthermore, mutations in human GM3 synthase have been linked to early-onset symptomatic epilepsy syndrome associated with developmental stagnation, blindness, and mitochondrial dysfunction [54,55]. In a study on epileptic patients, quantitative changes in major ganglioside species have been reported, indicating increased expression and immunohistochemical localization of the GD3 ganglioside in the hippocampi of epileptic patients [56]. Ganglioside GD3 is normally present in negligible amounts in the adult human brain; therefore, finding an increase of GD3 in hippocampal tissue in epilepsy is quite compelling. Given that GD3 binds calcium ions with a high-affinity [57,58], accumulation of GD3 may increase the local concentration of extracellular calcium ions, resulting in hyperexcitability. West syndrome, an infantile epilepsy disorder associated with developmental arrest or regression, has also been linked to several mutations in genes involved in ganglioside biosynthesis. Decreased levels of gangliosides GM1 and GD1a were observed in affected patients [59]. Furthermore, mutations in the *ST3GAL3* gene, coding for ST3 beta-galactoside α -2,3-sialyltransferase

3, were observed in patients with West syndrome [60], and in two infants suffering from epileptic encephalopathy [61]. Since this enzyme catalyzes the sialylation of glycoproteins in addition to glycolipids in animal models [62], this may suggest that variations in the sialylation pattern on the surface of neuronal cells may cause subtle changes in tissue glycolipid composition that could result in the occurrence of epilepsy [60]. Deficits in another enzyme in the ganglioside biosynthesis pathway, the GM2/GD2 synthase encoded by the *B4GALNT1* gene, cause rare hereditary spastic paraplegia accompanied by intellectual and motor disabilities [63], concurrent with severe motor deficits, progressive dysmyelination, and axonal degeneration shown in *B4galnt1-null* mice [64–66]. Studies on mice lacking the GM2/GD2 synthase demonstrated an increased vulnerability of the mice to seizures and the ability of a semisynthetic analog of ganglioside GM1, LIGA 20, to attenuate seizures when administered intraperitoneally [67]. Administration of gangliosides GM1 and GT1b have been reported to stop induced convulsions in animal models [68,69], whilst higher levels of GQ1b ganglioside have been shown to cause seizures in amygdaloid kindling-mice [70]. In the study on amygdaloid kindling-mice, intracerebroventricular administration of total brain gangliosides worsened kindling seizures [71]. Other experimental evidence also points to a complex role of gangliosides in the pathogenesis of seizures. A study on epileptic rats [72] has shown a decrease of the total content of GM1, GD1a, GD1b and GT1b gangliosides, phospholipids, NKA activity and lipid peroxidation levels following seizures. These data indicate that seizure activity leads to changed lipid content and lipid peroxidation status, in addition to altered NKA activity. The authors suggest that all the stated parameters might contribute to the neurophysiopathology of seizures observed in patients suffering from epilepsy [72]. However, the question remains whether the changes in the quantity of particular gangliosides in the brain are a consequence or the actual cause of different types of seizures by modulating functions of membrane proteins involved in seizure pathogenesis.

3. Na⁺/K⁺-ATPase

The Na⁺/K⁺-ATPase (NKA), or the sodium-potassium pump, is a ubiquitously expressed plasma membrane protein belonging to the family of P-type ATPases. This group of enzymes use the energy from ATP hydrolysis to pump ions over the plasma membrane against their concentration gradient by autophosphorylation of key aspartate residue [73,74]. NKA pumps 3 Na⁺ out of the cell and 2K⁺ into the cell per single molecule of ATP hydrolyzed, thus maintaining a higher concentration of sodium ions outside and a higher level of potassium ions inside the cell. Maintenance of the ionic imbalance between the cell and its surroundings by NKA is of great importance for cell physiology, providing for the stabilization of the resting membrane potential by hyperpolarization, firing up the action potential, ion homeostasis, osmotic regulation of the cell volume, cell cycle and metabolism regulation, regulation of endosomal pH, and various intracellular signal transduction pathways [75–78]. Being involved in all the above-mentioned processes, it is not surprising that the amount of energy consumption by NKA in brain grey matter is about three-quarters of the total energy expenditure of the brain [78]. Structurally, NKA is a heterodimer of a catalytic α subunit and regulative β subunit needed for positioning the catalytic subunit within the membrane [79]. A member of the FXYD family is also known to interact with the $\alpha\beta$ heterodimer [80] and different isoforms of particular subunits have been identified [73].

NKA is highly abundant in the brain and changes in its function and activity have been implicated in neurodegenerative disorders like Alzheimer's disease (AD) [81], with its expression being decreased both in the brain tissue derived from AD patients and AD mouse models [82,83]. Interaction between the neuron-specific $\alpha 3$ subunit and patient-derived A β oligomers was found to have a neurotoxic effect causing neurodegeneration by presynaptic calcium overload, resulting in hyperactivation of neurons [84]. Mutations in the α subunits have also been found in individuals with other neurodegenerative disorders—the rapid-onset dystonia-parkinsonism (RDP), alternating hemiplegia of childhood (AHC),

familial hemiplegic migraine (FHM), and hearing loss syndrome (CAPOS), all of which have overlapping symptoms including epileptic seizures, hyperactivity, dystonia, ataxia and cognitive deficits [85,86]. Contrary to the α subunits, no genetic neurodegenerative disorders are known to result from mutations in β and FXYP subunits [73].

Na⁺/K⁺-ATPase Involvement in Epileptic Seizures

Ionic currents that arise from the ionic imbalance between the cell and the intracellular space maintained by NKA activity have been hypothesized to cause seizures by several mechanisms. A decrease in NKA activity increases neuronal excitability which could underlie the pathogenesis of seizures [87]. Reduction of NKA current was demonstrated as crucial for the stability of the physiological network, as the increase in NKA current mediated termination of seizures due to elevation of intracellular Na⁺ concentrations [88]. Partial inhibition of NKA activity by cardiac glycoside ouabain caused rapid, running, and leaping seizures when injected to rat hippocampi, whilst clonic-tonic seizures occurred when the drug was administered to the cerebellum and the brainstem [89]. Administration of dyhydroouabain and strophanthidin led to decreased extracellular K⁺ levels and increased Ca²⁺ conductance contributing to epileptic discharges in CA1 hippocampal regions of rats [90]. Strophanthidin was found to have different effects on NKA current between rat CA1 and CA3 regions, with higher depolarization observed in the CA3 region, suggesting the region is more adaptive to epileptiform events [91]. Depolarization of neuronal membranes as a consequence of decreased NKA activity was also observed in neurons derived from patients suffering from chorea-acanthocytosis, a rare neurodegenerative disorder with manifestations of epileptic seizures [92]. A decrease in NKA activity has been observed in the epileptic human cerebral cortex, proposing that an abnormal flux of cations may lead to disturbed electrolyte metabolism in the epileptic brain [93].

Furthermore, there are a significant number of studies linking mutations in NKA genes to different epileptic phenotypes. A mutation in ATP1A1 gene coding for the α 1 catalytic subunit resulting in membrane depolarization was described in an infant suffering from lethal epilepsy [94]. Several mutations in ATP1A2 and ATP1A3 genes, encoding for α 2 and α 3 subunits, respectively, have been reported in a range of epileptic disorders, both in the brains of human subjects and mouse models [95]. FHM is a type of migraine with aura, with manifestations of epileptic seizures, cerebellar ataxia, and in more severe cases, coma. It was the first disorder to be linked to mutations in NKA subunits, as the loss of function of the α 2 subunit was detected [96–98]. Functional studies have revealed some of the mutations in the gene to result in a change of NKA kinetic parameters, rather than the total loss of the enzymatic activity [99–101]. More recently, seven distinct mutations in ATP1A2 have been selected by causing different phenotypes in FHM patients, all of whom resulted in a similar level of NKA protein expression, but with decreased enzyme activity compared to the control groups, and with more severe phenotypes having the lowest NKA activity [102]. Loss of α 2 function was detected in a cohort of seven patients with severe encephalic epilepsy carrying different mutations of the ATP1A2 gene [103]. A mutation has also been detected in two unrelated patients suffering from AHC, an early onset disorder outlined by epileptic seizures, ataxia, and learning disabilities [104]. Mutations in the ATP1A3 gene have been described in AHC as well, recognizing them as a key factor in AHC pathogenesis [105]. Several mutations in the gene resulting in a decrease of NKA activity were observed in children with AHC, but the mechanisms underlying the disorder remain unclear [106]. A study on an AHC mouse model carrying an α 3 missense mutation caused similar phenotypes of AHC in human patients [107]. The importance of NKA in epilepsy was confirmed in the Myshkin mouse model, carrying a sole mutation in the ATP1A3 gene causing total loss of NKA activity, leading to epileptiform activity and seizures in these mice [108]. The differences in clinical manifestations of various epileptic pathologies are the result of different positions and natures of sole mutations as different amino acid substitutions occur. The diversity of structural changes in α subunits might also

alter their ability to co-assemble with three β -isoforms and seven different FXYD domains, adding complexity to the elucidation of NKA involvement in epileptic seizures.

4. The Effects of Gangliosides on Na^+/K^+ -ATPase

To elucidate the interplay between gangliosides and NKA, firstly, we must focus on their intrinsic qualities given by their structural features. Gangliosides achieve a series of intra- and inter-molecular interactions that shape lateral and spatial membrane organization [109–111]. The ceramide part of the molecule accomplishes gangliosides' dense packing by accommodating cholesterol's steroid moiety in between two neighboring molecules [109]. In addition, experimental and computational evidence of the effective negative charge abolishment of the first sialic acid carboxylate ion, termed NH-trick, contributes to heavy packing [109,112]. This was previously suggested by Rodriguez et al. [112] who described the existence of a hydrogen bonding interaction between the hydrogen atom of the non-ionized carboxyl group in *N*-acetylneuraminic acid (Neu5Ac) and the oxygen atom of the carbonyl group in *N*-acetylgalactosamine (GalNAc), which reduces the dissociation of the Neu5Ac carboxyl group. Furthermore, they also suggested a second hydrogen bonding interaction between the proton of the acetamide group in GalNAc and the carbonyl moiety of the carboxyl group of Neu5Ac. The spatial organization of the oligosaccharide part differs depending on the topology of the microdomain where chalice-shaped conformers accessorize the outer borders, and flat-surfaced conformers occupy the interior [109]. The membrane's physical properties arising from these unique ganglioside characteristics include curvature, asymmetry, cooperativity, demixing, and metamorphism [90,91]. As gangliosides forge the local lipid environment in a range from nano- to micro-domain, they play a great role in setting up a functional environment for proteins associated with different membrane qualities. As a membrane protein, NKA demands specific lipids in its hydrophobic mismatch region. Although it encompasses a maximum of 33 annular lipids [113], the protein-lipid interface is populated with specific interaction partners revealed by mechanistic and structural studies involving NKA [113–115]. The interactive nature of NKA structural elements and membrane lipid constituents induces spatial stability and modulates ion-exchange frequency. Cholesterol can occupy two specific sites: (a) between the α and FXYD subunits, which favors stability, and (b) tightly squeezed between α and β subunits, disabling movement and pumping activity [114]. NKAs' dependence on cholesterol is evident from systems with cholesterol-poor membranes, e.g., *Saccharomyces cerevisiae*, where NKA resides in an inactive state with no detectable enzymatic turnover [114]. Furthermore, neutral phospholipids of inner membrane leaflets were suggested to stimulate NKA activity [114], and sphingomyelin and saturated phospholipids inhibit it [114]. Conceptually, NKA's enzymatic activity is a function of lateral lipid exchange within the annular region, and subtle changes of lipid species within NKA proximity can make enormous changes in the molecules' activity status. These events of lateral lipid mobility are within gangliosides' mixing-demixing ability [110], where gangliosides act as lipid sorting machinery providing the optimal *mise en scène* for a variety of proteins, including NKA. However, there have been only a minor number of studies on how gangliosides affect NKA enzymatic activity, performed on model or physiological systems. Our research group has established that NKA activity alternates during multiple freeze-thaw cycles due to reshuffling between lipid rafts and bulk membrane fractions accompanied by ganglioside GM1, and with GD1a, GD1b, and GT1b distribution mirroring the changes in NKA activity [116]. These results indicate that gangliosides arrange a distinct lipid environment crucial for proper NKA functioning. Hence, as opposed to investigating the effects on NKA by exogenously adding gangliosides, within real membranes the change of ganglioside composition is achieved between distinct membrane domains. Considering that different gangliosides populate different lipid rafts in various cell types [117], this could be an important means of fine-tuning NKA activity. Furthermore, described pools of non-pumping NKA in epithelial cells are a consequence of NKA positioning within membrane domains with different cholesterol concentrations,

caveolae and lipid rafts [118]. Extensive NKA mobility in neuronal membranes [119] could be ganglioside driven, thus utilizing proteins' different modes of operation and maintaining neuronal membrane homeostasis. Ganglioside-NKA interactions were also investigated by electron spin resonance (ESR) spectroscopy using spin-labeled gangliosides GM1, GM2, GM3, and GD1b and NKA purified from shark rectal glands, in conjunction with other charged membrane lipids. The results indicated gangliosides GM1, GM2, and GM3 exhibit virtually no selectivity in interactions with NKA relative to spin-labeled phosphatidylcholine, whilst GD1b selectivity was considerably lower relative to other phospholipids, possibly due to one more sialic acid residues in its structure [120]. The authors propose that this low selectivity is due to the bulkiness of ganglioside head groups which prevents closer associations with the protein.

Up to today, most of the studies on how gangliosides affect NKA activity have investigated the effects of the addition of exogenous gangliosides on NKA activity in various types of tissue preparations originating from different species, often resulting in contradictory results (Table 1).

Table 1. Summarized data describing the effect of exogenously added gangliosides on NKA activity.

Animal Model	Sample Type	Gangliosides Studied	NKA Activity	Publication
Chicken	Brain synaptosomes	Total porcine brain gangliosides	↓	[121]
Cat	Brain synaptosomes	GM1	No change	[122]
Rat	Brain microsomes	Total human brain gangliosides	↑↓ *	[123]
Rat	Brain microsomes	Total human brain gangliosides	↑	[124]
Rat	Brain mitochondrial fractions	GM1, GD1a, GD1b, GT1b	↑	[125]
Rat	SCG homogenates	GM1	↓	[126,127]
Rat	NG homogenates	GM1	↑	[127,128]
Mongolian gerbil	Brain homogenates	GM1	No change	[129,130]
Rat	Striatal homogenates	GM1	↑	[68]
Rat	Heart	GM1	↑	[131]
Rat	Nerve homogenates	Mixed bovine gangliosides	↑	[132]

* lower concentrations were shown to activate and higher to inhibit NKA activity. SCG = superior cervical ganglion, NG = nodose ganglia.

Total brain gangliosides isolated from porcine brains reduced NKA activity up to 40% in chicken brain synaptosomal preparations when ganglioside-protein ratios were 1:1, with the kinetics described as a non-competitive inhibition, and the interactions being dependent on temperature, ATP concentration, and preincubation time [121]. Interestingly, the increase in ganglioside concentrations was found not to affect NKA activity in synaptosomal fractions derived from cats suffering from GM1 and GM2 gangliosidosis [122]. In another study on rat brain microsomal preparations, administration of total human brain gangliosides had opposite effects regarding their concentration. The lower concentrations were shown to activate and higher to inhibit NKA activity, with the inhibition being reversible and competitive relative to K⁺ concentrations [123]. The authors suggest that the inhibition of NKA activity results from conformational changes in the membrane caused by the inte-

gration of exogenous gangliosides. In another study, microsomal fractions from adult male rats were treated with total brain gangliosides and various sphingolipid species derived from a patient with Tay–Sachs disease resulting in slight activation of NKA activity [124]. Furthermore, the addition of nanomolar concentrations of exogenous GM1, GD1a, GD1b, GT1b gangliosides to mitochondrial fractions derived from rat brains caused a 26–43% rise in NKA activity under identical conditions, with authors suggesting the phenomenon to be directly linked to alternations in the enzyme’s lipid environment [125]. All the above findings reflected in NKA activity alterations affirm that gangliosides affect the membrane in a different manner depending on membrane specialization and complexity. Ganglioside GM1 itself was found to cause minor inhibition of NKA activity when added to homogenates prepared from rat superior cervical ganglion (SCG) [126,127], but an increase in the activity in nodose ganglia (NG) from adult rats [127,128]. Administration of ganglioside GM1 has been shown to have potential therapeutic properties since it was able to decrease mortality due to ischemia up to 52% in Mongolian gerbils. However, no significant differences were observed in NKA activity between occluded and non-occluded brain hemispheres [129]. The same group has again observed neuroprotective action of GM1 in comparison to the saline treatment of induced ischemia in the gerbil cerebral cortex [130]. In another study, striatal homogenates derived from rat brains injected with convulsion-causing glutaric acid (GA) and pentylenetetrazole (PTZ) were incubated with GM1. A decrease in NKA activity resulting from GA administration was shown to cause seizures *in vivo*, and an *ex vivo* decrease in NKA activity to be prevented by GM1 administration, suggesting its possible therapeutic application in the treatment of seizures [68]. More recently, ganglioside GM1 was also found to have neuroprotective properties in hippocampal homogenates from AD models, as it was able to prevent the decrease in NKA activity caused by the A β 1-42 oligomer administration [133]. GM1 administration was also shown to reduce the effects of hypoxia-reoxygenation in rat heart, as it was able to stabilize NKA activity which was decreased due to hypoxic conditions [131]. In addition, a complete correction of a decrease in NKA activity in nerve homogenates from diabetic rats treated with mixed bovine gangliosides was observed over a five-week period [132].

5. Conclusions

The purpose of this review was to map out the many possible points of convergence between gangliosides and NKA, which in tandem lead to the development of epileptic seizures if their respective functions are disturbed. The presented evidence may serve as a direction for new experimental approaches to investigate the observed phenomena in detail. We explore a select facet of neuronal membrane dynamic environment which may have crucial impact on ion homeostasis and pathological ion imbalance. We propose that specific sets of gangliosides and NKA possibly form highly functional assemblies within membranes. We summarize the overwhelming experimental evidence on the intricate relationship between NKA and gangliosides, which includes: (i) Exogenously added gangliosides have a measurable effect on NKA activity. The demonstrated change in activity of NKA is found to be concentration-dependent and specific ganglioside species exert different responses in NKA activity [121–130]; (ii) Ganglioside-NKA interactions studied by electron spin resonance spectroscopy show differential selectivity in interactions between gangliosides and NKA [120]; (iii) Impaired NKA activity is restored following ganglioside treatment in models of different pathological conditions, including seizures caused by glutaric acid administration, Alzheimer’s disease model, hypoxic conditions and diabetes [68,131–133]. Certain neuroprotective effects of specific gangliosides are suggested to be mediated through modulation of NKA activity [133]. We therefore argue that structural changes of neuronal membrane caused by altered ganglioside composition most likely contribute to aberrant NKA activity, with the resulting ion imbalance priming neurons for pathological firing (Figure 1).




Figure 1. Schematic representation of sequence of events leading from altered ganglioside composition of the neuronal membrane to pathological firing of neurons and epileptic seizures. Na^+/K^+ -ATPase (NKA) positioning is heavily influenced by the surrounding gangliosides. NKA is represented by [Biorender.com](https://www.biorender.com) (accessed on 26 April 2022), relying on PDB accession code 3B8E, according to [134], utilizing the Van Der Waals structure style and Hydrophobicity color style. Red color represents amino acids with more hydrophobic side chains, and blue represents amino acids with more hydrophilic side chains. Gangliosides (in space-filling model) are shown in purple.

The existence of specific functional interaction(s) between gangliosides and NKA, is of immense significance for properties of neuronal membranes, and is strongly corroborated by different epileptic phenotypes in humans and murine models caused by either impaired activity of NKA or changed membrane ganglioside composition. Clarifying the exact effect of gangliosides on NKA activity may greatly contribute to understanding the complexity of well-regulated molecular events involved in maintenance of neuronal membrane ion homeostasis. Since the administration of gangliosides to patients suffering from various neuropathological conditions is being intensely investigated [135,136], the research avenues which would take into account the suggested NKA-gangliosides partnership may reveal new molecular targets in diagnosis and treatment of epilepsy.

Author Contributions: Conceptualization, B.P., M.S., K.I., S.K.-B. and K.M.-J.; writing—original draft preparation, B.P., M.S. and K.I.; writing—review and editing, S.K.-B. and K.M.-J.; supervision, S.K.-B. and K.M.-J.; funding acquisition, S.K.-B. All authors have read and agreed to the published version of the manuscript.

Funding: The authors were supported by the Croatian Science Foundation, “NeuroReact” project (IP 2016-06-8636, PI: SKB), and the Scientific Centre of Excellence for Basic, Clinical, and Translational Neuroscience (project “Experimental and clinical research of hypoxic ischemic damage in perinatal and adult brain” GA KK 01.1.1.01.0007 funded by the European Union through the European Regional Development Fund).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Graphical abstract and Figure 1 were created with [BioRender.com](https://www.biorender.com) (agreement numbers NJ23TO7LGU and XV23U5H3V5, accessed on 26 April 2022).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Pinigin, K.V.; Kondrashov, O.V.; Jiménez-Munigua, I.; Alexandrova, V.V.; Batishchev, O.; Galimzyanov, T.R.; Akimov, S.A. Elastic Deformations Mediate Interaction of the Raft Boundary with Membrane Inclusions Leading to Their Effective Lateral Sorting. *Sci. Rep.* **2020**, *10*, 4087. [[CrossRef](#)] [[PubMed](#)]
2. Bodosa, J.; Iyer, S.S.; Srivastava, A. Preferential Protein Partitioning in Biological Membrane with Coexisting Liquid Ordered and Liquid Disordered Phase Behavior: Underlying Design Principles. *J. Membr. Biol.* **2020**, *253*, 551–562. [[CrossRef](#)] [[PubMed](#)]
3. Ebersberger, L.; Schindler, T.; Kirsch, S.A.; Pluhackova, K.; Schambony, A.; Seydel, T.; Böckmann, R.A.; Unruh, T. Lipid Dynamics in Membranes Slowed Down by Transmembrane Proteins. *Front. Cell Dev. Biol.* **2020**, *8*, 1120. [[CrossRef](#)] [[PubMed](#)]
4. Nyholm, T.K.M. Lipid-Protein Interplay and Lateral Organization in Biomembranes. *Chem. Phys. Lipids* **2015**, *189*, 48–55. [[CrossRef](#)]
5. Muller, M.P.; Jiang, T.; Sun, C.; Lihan, M.; Pant, S.; Mahinthichaichan, P.; Trifan, A.; Tajkhorshid, E. Characterization of Lipid-Protein Interactions and Lipid-Mediated Modulation of Membrane Protein Function through Molecular Simulation. *Chem. Rev.* **2019**, *119*, 6086–6161. [[CrossRef](#)]
6. Laganowsky, A.; Reading, E.; Allison, T.M.; Ulmschneider, M.B.; Degiacomi, M.T.; Baldwin, A.J.; Robinson, C.V. Membrane Proteins Bind Lipids Selectively to Modulate Their Structure and Function. *Nature* **2014**, *510*, 172–175. [[CrossRef](#)]
7. Sarkis, J.; Vié, V. Biomimetic Models to Investigate Membrane Biophysics Affecting Lipid-Protein Interaction. *Front. Bioeng. Biotechnol.* **2020**, *8*, 270. [[CrossRef](#)]
8. Zheng, Y.; Liu, H.; Chen, Y.; Dong, S.; Wang, F.; Wang, S.; Li, G.L.; Shu, Y.; Xu, F. Structural Insights into the Lipid and Ligand Regulation of a Human Neuronal KCNQ Channel. *Neuron* **2022**, *110*, 237–247.e4. [[CrossRef](#)]
9. Corradi, V.; Mendez-Villuendas, E.; Ingólfsson, H.I.; Gu, R.X.; Siuda, I.; Melo, M.N.; Moussatova, A.; Degagné, L.J.; Sejdiu, B.I.; Singh, G.; et al. Lipid-Protein Interactions Are Unique Fingerprints for Membrane Proteins. *ACS Cent. Sci.* **2018**, *4*, 709–717. [[CrossRef](#)]
10. Hedger, G.; Sansom, M.S.P. Lipid Interaction Sites on Channels, Transporters and Receptors: Recent Insights from Molecular Dynamics Simulations. *Biochim. Biophys. Acta Biomembr.* **2016**, *1858*, 2390–2400. [[CrossRef](#)]
11. Stansfeld, P.J.; Sansom, M.S.P. Molecular Simulation Approaches to Membrane Proteins. *Structure* **2011**, *19*, 1562–1572. [[CrossRef](#)]
12. Bostick, D.L.; Berkowitz, M.L. Exterior Site Occupancy Infers Chloride-Induced Proton Gating in a Prokaryotic Homolog of the ClC Chloride Channel. *Biophys. J.* **2004**, *87*, 1686–1696. [[CrossRef](#)]
13. Domene, C.; Grottesi, A.; Sansom, M.S.P. Filter Flexibility and Distortion in a Bacterial Inward Rectifier K⁺ Channel: Simulation Studies of KirBac1.1. *Biophys. J.* **2004**, *87*, 256–267. [[CrossRef](#)]
14. Hung, A.; Tai, K.; Sansom, M.S.P. Molecular Dynamics Simulation of the M2 Helices within the Nicotinic Acetylcholine Receptor Transmembrane Domain: Structure and Collective Motions. *Biophys. J.* **2005**, *88*, 3233–3321. [[CrossRef](#)]
15. Bond, P.J.; Faraldo-Gómez, J.D.; Sansom, M.S.P. OmpA: A Pore or Not a Pore? Simulation and Modeling Studies. *Biophys. J.* **2002**, *83*, 763–775. [[CrossRef](#)]
16. Faraldo-Gómez, J.D.; Smith, G.R.; Sansom, M.S.P. Molecular Dynamics Simulations of the Bacterial Outer Membrane Protein FhuA: A Comparative Study of the Ferrichrome-Free and Bound States. *Biophys. J.* **2003**, *85*, 1406–1420. [[CrossRef](#)]
17. Chavent, M.; Duncan, A.L.; Sansom, M.S.P. Molecular Dynamics Simulations of Membrane Proteins and Their Interactions: From Nanoscale to Mesoscale. *Curr. Op. Struct. Biol.* **2016**, *40*, 8–16. [[CrossRef](#)]
18. Javanainen, M. Universal Method for Embedding Proteins into Complex Lipid Bilayers for Molecular Dynamics Simulations. *J. Chem. Theory Comput.* **2014**, *10*, 2577–2582. [[CrossRef](#)]
19. Kato, K.; Yamaguchi, T.; Yagi-Utsumi, M. Experimental and Computational Characterization of Dynamic Biomolecular Interaction Systems Involving Glycolipid Glycans. *Glycoconj. J.* **2022**, *39*, 219–228. [[CrossRef](#)]
20. De Oliveira, E.C.L.; da Costa, K.S.; Taube, P.S.; Lima, A.H.; de Souza de Sales, C., Jr. Biological Membrane-Penetrating Peptides: Computational Prediction and Applications. *Front. Cell. Infect. Microbiol.* **2022**, *12*, 276. [[CrossRef](#)]
21. Yang, X.; Lin, C.; Chen, X.; Li, S.; Li, X.; Xiao, B. Structure Deformation and Curvature Sensing of PIEZO1 in Lipid Membranes. *Nature* **2022**, *604*, 377–383. [[CrossRef](#)]
22. Lee, I.H.; Imanaka, M.Y.; Modahl, E.H.; Torres-Ocampo, A.P. Lipid Raft Phase Modulation by Membrane-Anchored Proteins with Inherent Phase Separation Properties. *ACS Omega* **2019**, *4*, 6551–6559. [[CrossRef](#)]
23. Cornell, C.E.; Mileant, A.; Thakkar, N.; Lee, K.K.; Keller, S.L. Direct Imaging of Liquid Domains in Membranes by Cryo-Electron Tomography. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 19713–19719. [[CrossRef](#)]
24. Leitao, S.M.; Drake, B.; Pinjusic, K.; Pierrat, X.; Navikas, V.; Nievergelt, A.P.; Brillard, C.; Djekic, D.; Radenovic, A.; Persat, A.; et al. Time-Resolved Scanning Ion Conductance Microscopy for Three-Dimensional Tracking of Nanoscale Cell Surface Dynamics. *ACS Nano* **2021**, *15*, 17613–17622. [[CrossRef](#)]
25. Flores, A.; Ramirez-Franco, J.; Desplantes, R.; Debreux, K.; Ferracci, G.; Wernert, F.; Blanchard, M.P.; Maulet, Y.; Youssouf, F.; Sangiardi, M.; et al. Gangliosides Interact with Synaptotagmin to Form the High-Affinity Receptor Complex for Botulinum Neurotoxin B. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 18098–18108. [[CrossRef](#)]
26. Gu, R.X.; Ingólfsson, H.I.; De Vries, A.H.; Marrink, S.J.; Tieleman, D.P. Ganglioside-Lipid and Ganglioside-Protein Interactions Revealed by Coarse-Grained and Atomistic Molecular Dynamics Simulations. *J. Phys. Chem. B* **2017**, *121*, 3262–3275. [[CrossRef](#)]
27. Sipione, S.; Monyror, J.; Galleguillos, D.; Steinberg, N.; Kadam, V. Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications. *Front. Neurosci.* **2020**, *14*, 1004. [[CrossRef](#)]

28. Prinetti, A.; Loberto, N.; Chigorno, V.; Sonnino, S. Glycosphingolipid Behaviour in Complex Membranes. *Biochim. Biophys. Acta Biomembr.* **2009**, *1788*, 184–193. [[CrossRef](#)]
29. Yamakawa, T. Thus Started Ganglioside Research. *Trends Biochem. Sci.* **1988**, *13*, 452–454. [[CrossRef](#)]
30. Kolter, T. Ganglioside Biochemistry. *ISRN Biochem.* **2012**, *2012*, 506160. [[CrossRef](#)]
31. Schnaar, R.L. Gangliosides of the Vertebrate Nervous System. *J. Mol. Biol.* **2016**, *428*, 3325–3336. [[CrossRef](#)] [[PubMed](#)]
32. Kračun, I.; Rösner, H.; Čosović, C.; Stavljenič, A. Topographical Atlas of the Gangliosides of the Adult Human Brain. *J. Neurochem.* **1984**, *43*, 979–989. [[CrossRef](#)] [[PubMed](#)]
33. Yamaji, T.; Hanada, K. Sphingolipid Metabolism and Interorganellar Transport: Localization of Sphingolipid Enzymes and Lipid Transfer Proteins. *Traffic* **2015**, *16*, 101–122. [[CrossRef](#)] [[PubMed](#)]
34. Echten-Deckert, G.; Guravi, M. Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis. *Curr. Drug Targets* **2008**, *9*, 282–291. [[CrossRef](#)]
35. Mlinac, K.; Bogner, S.K. Role of Gangliosides in Brain Aging and Neurodegeneration. *Transl. Neurosci.* **2010**, *1*, 300–307. [[CrossRef](#)]
36. Schnaar, R.L. The Biology of Gangliosides. *Adv. Carbohydr. Chem. Biochem.* **2019**, *76*, 113–148. [[CrossRef](#)]
37. Li, T.A.; Schnaar, R.L. Congenital Disorders of Ganglioside Biosynthesis. *Prog. Mol. Biol. Transl. Sci.* **2018**, *156*, 63–82. [[CrossRef](#)]
38. Sarmiento, M.J.; Ricardo, J.C.; Amaro, M.; Sachl, R.; J Sarmiento, C.M.; Sachl, R.; Heyrovsk, J. Organization of Gangliosides into Membrane Nanodomains. *FEBS Lett.* **2020**, *594*, 3668–3697. [[CrossRef](#)]
39. Sonnino, S.; Chiricozzi, E.; Grassi, S.; Mauri, L.; Prioni, S.; Prinetti, A. Gangliosides in Membrane Organization. *Prog. Mol. Biol. Transl. Sci.* **2018**, *156*, 83–120. [[CrossRef](#)]
40. Julien, S.; Bobowski, M.; Steenackers, A.; Le Bourhis, X.; Delannoy, P. How Do Gangliosides Regulate RTKs Signaling? *Cells* **2013**, *2*, 751–767. [[CrossRef](#)]
41. Ilic, K.; Auer, B.; Mlinac-Jerkovic, K.; Herrera-Molina, R. Neuronal Signaling by Thy-1 in Nanodomains with Specific Ganglioside Composition: Shall We Open the Door to a New Complexity? *Front. Cell Dev. Biol.* **2019**, *7*, 27. [[CrossRef](#)]
42. Ilic, K.; Lin, X.; Malci, A.; Stojanović, M.; Puljko, B.; Rožman, M.; Vukelić, Ž.; Heffer, M.; Montag, D.; Schnaar, R.L.; et al. Plasma Membrane Calcium ATPase-Neuroplastin Complexes Are Selectively Stabilized in GM1-Containing Lipid Rafts. *Int. J. Mol. Sci.* **2021**, *22*, 3590. [[CrossRef](#)]
43. Yoon, S.J.; Nakayama, K.I.; Hikita, T.; Handa, K.; Hakomori, S.I. Epidermal Growth Factor Receptor Tyrosine Kinase Is Modulated by GM3 Interaction with N-Linked GlcNAc Termini of the Receptor. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 18987–18991. [[CrossRef](#)]
44. Kabayama, K.; Sato, T.; Saito, K.; Loberto, N.; Prinetti, A.; Sonnino, S.; Kinjo, M.; Igarashi, Y.; Inokuchi, J.I. Dissociation of the Insulin Receptor and Caveolin-1 Complex by Ganglioside GM3 in the State of Insulin Resistance. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 13678–13683. [[CrossRef](#)]
45. De Laurentiis, A.; Donovan, L.; Arcaro, A. Lipid Rafts and Caveolae in Signaling by Growth Factor Receptors. *Open Biochem. J.* **2007**, *1*, 12. [[CrossRef](#)]
46. Prendergast, J.; Umanah, G.K.E.; Yoo, S.W.; Lagerlöf, O.; Motari, M.G.; Cole, R.N.; Haganir, R.L.; Dawson, T.M.; Dawson, V.L.; Schnaar, R.L. Ganglioside Regulation of AMPA Receptor Trafficking. *J. Neurosci.* **2014**, *34*, 13246–13258. [[CrossRef](#)]
47. Ichikawa, N.; Iwabuchi, K.; Kurihara, H.; Ishii, K.; Kobayashi, T.; Sasaki, T.; Hattori, N.; Mizuno, Y.; Hozumi, K.; Yamada, Y.; et al. Binding of Laminin-1 to Monosialoganglioside GM1 in Lipid Rafts Is Crucial for Neurite Outgrowth. *J. Cell Sci.* **2009**, *122*, 289–299. [[CrossRef](#)]
48. Scheffer, I.E.; Berkovic, S.; Capovilla, G.; Connolly, M.B.; French, J.; Guilhoto, L.; Hirsch, E.; Jain, S.; Mathern, G.W.; Moshé, S.L.; et al. ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* **2017**, *58*, 512–521. [[CrossRef](#)]
49. Falco-Walter, J.J.; Scheffer, I.E.; Fisher, R.S. The New Definition and Classification of Seizures and Epilepsy. *Epilepsy Res.* **2018**, *139*, 73–79. [[CrossRef](#)]
50. McCormick, D.A.; Contreras, D. On the Cellular and Network Bases of Epileptic Seizures. *Annu. Rev. Physiol.* **2001**, *63*, 815–846. [[CrossRef](#)]
51. Boccuto, L.; Aoki, K.; Flanagan-Steet, H.; Chen, C.F.; Fan, X.; Bartel, F.; Petukh, M.; Pittman, A.; Saul, R.; Chaubey, A.; et al. A Mutation in a Ganglioside Biosynthetic Enzyme, ST3GAL5, Results in Salt & Pepper Syndrome, a Neurocutaneous Disorder with Altered Glycolipid and Glycoprotein Glycosylation. *Hum. Mol. Genet.* **2014**, *23*, 418–433. [[CrossRef](#)]
52. Yamashita, T.; Hashiramoto, A.; Haluzik, M.; Mizukami, H.; Beck, S.; Norton, A.; Kono, M.; Tsuji, S.; Daniotti, J.L.; Werth, N.; et al. Enhanced Insulin Sensitivity in Mice Lacking Ganglioside GM3. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 3445–3449. [[CrossRef](#)]
53. Kawai, H.; Allende, M.L.; Wada, R.; Kono, M.; Sango, K.; Deng, C.; Miyakawa, T.; Crawley, J.N.; Werth, N.; Bierfreund, U.; et al. Mice Expressing Only Monosialoganglioside GM3 Exhibit Lethal Audiogenic Seizures. *J. Biol. Chem.* **2001**, *276*, 6885–6888. [[CrossRef](#)]
54. Simpson, M.A.; Cross, H.; Proukakis, C.; Priestman, D.A.; Neville, D.C.A.; Reinkensmeier, G.; Wang, H.; Wiznitzer, M.; Gurtz, K.; Verganelaki, A.; et al. Infantile-Onset Symptomatic Epilepsy Syndrome Caused by a Homozygous Loss-of-Function Mutation of GM3 Synthase. *Nat. Genet.* **2004**, *36*, 1225–1229. [[CrossRef](#)]
55. Fragaki, K.; Ait-El-Mkadem, S.; Chausseot, A.; Gire, C.; Mengual, R.; Bonesso, L.; Beneteau, M.; Ricci, J.E.; Desquirit-Dumas, V.; Procaccio, V.; et al. Refractory Epilepsy and Mitochondrial Dysfunction Due to GM3 Synthase Deficiency. *Eur. J. Hum. Genet.* **2013**, *21*, 528–534. [[CrossRef](#)]

56. Yu, R.K.; Holley, J.A.; Macala, L.J.; Spencer, D.D. Ganglioside Changes Associated with Temporal Lobe Epilepsy in the Human Hippocampus. *Yale J. Biol. Med.* **1987**, *60*, 107.
57. Abramson, M.B.; Yu, R.K.; Zaby, V. Ionic Properties of Beef Brain Gangliosides. *Biochim. Biophys. Acta Lipids Lipid Metab.* **1972**, *280*, 365–372. [[CrossRef](#)]
58. Behr, J.P.; Lehn, J.M. The Binding of Divalent Cations by Purified Gangliosides. *FEBS Lett.* **1973**, *31*, 297–300. [[CrossRef](#)]
59. Izumi, T.; Ogawa, T.; Koizumi, H.; Fukuyama, Y. Low Levels of CSF Gangliotetraose-Series Gangliosides in West Syndrome: Implication of Brain Maturation Disturbance. *Pediatr. Neurol.* **1993**, *9*, 293–296. [[CrossRef](#)]
60. Van Diepen, L.; Buettner, F.F.R.; Hoffmann, D.; Thiesler, C.T.; von Bohlen und Halbach, O.; von Bohlen und Halbach, V.; Jensen, L.R.; Steinemann, D.; Edvardson, S.; Elpeleg, O.; et al. A Patient-Specific Induced Pluripotent Stem Cell Model for West Syndrome Caused by ST3GAL3 Deficiency. *Eur. J. Hum. Genet.* **2018**, *26*, 1773–1783. [[CrossRef](#)]
61. Indelicato, R.; Domenighini, R.; Malagolini, N.; Cereda, A.; Mamoli, D.; Pezzani, L.; Iascone, M.; Dall’olio, F.; Trinchera, M. A Novel Nonsense and Inactivating Variant of ST3GAL3 in Two Infant Siblings Suffering Severe Epilepsy and Expressing Circulating CA19.9. *Glycobiology* **2020**, *30*, 95–104. [[CrossRef](#)] [[PubMed](#)]
62. Sturgill, E.R.; Aoki, K.; Lopez, P.H.H.; Colacurcio, D.; Vajn, K.; Lorenzini, I.; Majić, S.; Yang, W.H.; Heffer, M.; Tiemeyer, M.; et al. Biosynthesis of the Major Brain Gangliosides GD1a and GT1b. *Glycobiology* **2012**, *22*, 1289–1301. [[CrossRef](#)] [[PubMed](#)]
63. Harlalka, G.V.; Lehman, A.; Chioza, B.; Baple, E.L.; Maroofian, R.; Cross, H.; Sreekantan-Nair, A.; Priestman, D.A.; Al-Turki, S.; McEntagart, M.E.; et al. Mutations in B4GALNT1 (GM2 Synthase) Underlie a New Disorder of Ganglioside Biosynthesis. *Brain* **2013**, *136*, 3618–3624. [[CrossRef](#)] [[PubMed](#)]
64. Chiavegatto, S.; Sun, J.; Nelson, R.J.; Schnaar, R.L. A Functional Role for Complex Gangliosides: Motor Deficits in GM2/GD2 Synthase Knockout Mice. *Exp. Neurol.* **2000**, *166*, 227–234. [[CrossRef](#)]
65. Pan, B.; Fromholt, S.E.; Hess, E.J.; Crawford, T.O.; Griffin, J.W.; Sheikh, K.A.; Schnaar, R.L. Myelin-Associated Glycoprotein and Complementary Axonal Ligands, Gangliosides, Mediate Axon Stability in the CNS and PNS: Neuropathology and Behavioral Deficits in Single- and Double-Null Mice. *Exp. Neurol.* **2005**, *195*, 208–217. [[CrossRef](#)]
66. Takamiya, K.; Yamamoto, A.; Furukawa, K.; Yamashiro, S.; Shin, M.; Okada, M.; Fukumoto, S.; Haraguchi, M.; Takeda, N.; Fujimura, K.; et al. Mice with Disrupted GM2/GD2 Synthase Gene Lack Complex Gangliosides but Exhibit Only Subtle Defects in Their Nervous System. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 10662–10667. [[CrossRef](#)]
67. Wu, G.; Lu, Z.-H.; Wang, J.; Wang, Y.; Xie, X.; Meyenhofer, M.F.; Ledeen, R.W. Neurobiology of Disease Enhanced Susceptibility to Kainate-Induced Seizures, Neuronal Apoptosis, and Death in Mice Lacking Gangliotetraose Gangliosides: Protection with LIGA 20, a Membrane-Permeant Analog of GM1. *J. Neurosci.* **2005**, *25*, 11014–11022. [[CrossRef](#)]
68. Figuera, M.R.; Royes, L.F.F.; Furian, A.F.; Oliveira, M.S.; Fiorenza, N.G.; Frussa-Filho, R.; Petry, J.C.; Coelho, R.C.; Mello, C.F. GM1 Ganglioside Prevents Seizures, Na⁺,K⁺-ATPase Activity Inhibition and Oxidative Stress Induced by Glutaric Acid and Pentylentetrazole. *Neurobiol. Dis.* **2006**, *22*, 611–623. [[CrossRef](#)]
69. Yamamoto, H.; Tsuji, S.; Nagai, Y. Tetrasialoganglioside GO1b Reactive Monoclonal Antibodies: Their Characterization and Application for Quantification of GQ1b in Some Cell Lines of Neuronal and Adrenal Origin(s). *J. Neurochem.* **1990**, *54*, 513–517. [[CrossRef](#)]
70. Kato, K.; Iwamori, M.; Hirabayashi, Y. Increase of GQ1b in the Hippocampus of Mice Following Kindled-Seizures. *Neurosci. Lett.* **2008**, *441*, 286–290. [[CrossRef](#)]
71. Nakamura, Y.; Morimoto, K.; Okamoto, M. Modification of Amygdala Kindling by Intracerebroventricularly Administered Gangliosides in Rats. *Exp. Neurol.* **1989**, *106*, 61–69. [[CrossRef](#)]
72. De Freitas, R.M.; do Nascimento, K.G.; Ferreira, P.M.P.; Jordán, J. Neurochemical Changes on Oxidative Stress in Rat Hippocampus during Acute Phase of Pilocarpine-Induced Seizures. *Pharmacol. Biochem. Behav.* **2010**, *94*, 341–345. [[CrossRef](#)]
73. Clausen, M.V.; Hilbers, F.; Poulsen, H. The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease. *Front. Physiol.* **2017**, *8*, 371. [[CrossRef](#)]
74. Yoneda, J.S.; Sebinelli, H.G.; Itri, R.; Ciancaglini, P. Overview on Solubilization and Lipid Reconstitution of Na,K-ATPase: Enzyme Kinetic and Biophysical Characterization. *Biophys. Rev.* **2020**, *12*, 49–64. [[CrossRef](#)]
75. Forrest, M.D. The Sodium-Potassium Pump Is an Information Processing Element in Brain Computation. *Front. Physiol.* **2014**, *5*, 472. [[CrossRef](#)]
76. Boldyrev, A.; Bulygina, E.; Gerassimova, O.; Lyapina, L.; Schoner, W. Functional Relationship between Na/K-ATPase and NMDA-Receptors in Rat Cerebellum Granule Cells. *Biochem. Mosc.* **2004**, *69*, 429–434. [[CrossRef](#)]
77. Fuchs, R.; Schmid, S.; Mellman, I. A Possible Role for Na⁺,K⁺-ATPase in Regulating ATP-Dependent Endosome Acidification. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 539–543. [[CrossRef](#)]
78. Attwell, D.; Laughlin, S.B. An Energy Budget for Signaling in the Grey Matter of the Brain. *J. Cereb. Blood Flow Metab.* **2001**, *21*, 1133–1145. [[CrossRef](#)]
79. Jørgensen, P.L.; Andersen, J.P. Structural Basis for E1-E2 Conformational Transitions in Na,K-Pump and Ca-Pump Proteins. *J. Membr. Biol.* **1988**, *103*, 95–120. [[CrossRef](#)]
80. Sweadner, K.J.; Rael, E. The FXFD Gene Family of Small Ion Transport Regulators or Channels: CDNA Sequence, Protein Signature Sequence, and Expression. *Genomics* **2000**, *68*, 41–56. [[CrossRef](#)]
81. Zhang, L.N.; Sun, Y.J.; Pan, S.; Li, J.X.; Qu, Y.E.; Li, Y.; Wang, Y.L.; Gao, Z. Bin Na⁺-K⁺-ATPase, a Potent Neuroprotective Modulator against Alzheimer Disease. *Fundam. Clin. Pharmacol.* **2013**, *27*, 96–103. [[CrossRef](#)]

82. Chauhan, N.B.; Lee, J.M.; Siegel, G.J. Na,K-ATPase mRNA Levels and Plaque Load in Alzheimer's Disease. *J. Mol. Neurosci.* **1997**, *9*, 151–166. [[CrossRef](#)]
83. Fu, Y.J.; Xiong, S.; Lovell, M.A.; Lynn, B.C. Quantitative Proteomic Analysis of Mitochondria in Aging PS-1 Transgenic Mice. *Cell. Mol. Neurobiol.* **2009**, *29*, 649–694. [[CrossRef](#)]
84. Ohnishi, T.; Yanazawa, M.; Sasahara, T.; Kitamura, Y.; Hiroaki, H.; Fukazawa, Y.; Kii, I.; Nishiyama, T.; Kakita, A.; Takeda, H.; et al. Na,K-ATPase A3 Is a Death Target of Alzheimer Patient Amyloid- β Assembly. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, E4465–E4474. [[CrossRef](#)]
85. Holm, T.H.; Isaksen, T.J.; Glerup, S.; Heuck, A.; Böttger, P.; Füchtbauer, E.M.; Nedergaard, S.; Nyengaard, J.R.; Andreasen, M.; Nissen, P.; et al. Cognitive Deficits Caused by a Disease-Mutation in the A3 Na(+)/K(+)-ATPase Isoform. *Sci. Rep.* **2016**, *6*, 31972. [[CrossRef](#)]
86. Sweney, M.T.; Newcomb, T.M.; Swoboda, K.J. The Expanding Spectrum of Neurological Phenotypes in Children with ATP1A3 Mutations, Alternating Hemiplegia of Childhood, Rapid-Onset Dystonia-Parkinsonism, CAPOS and Beyond. *Pediatr. Neurol.* **2015**, *52*, 56–64. [[CrossRef](#)]
87. Funck, V.R.; Ribeiro, L.R.; Pereira, L.M.; de Oliveira, C.V.; Grigoletto, J.; Della-Pace, I.D.; Figuera, M.R.; Royes, L.F.F.; Furian, A.F.; Larrick, J.W.; et al. Contrasting Effects of Na⁺,K⁺-ATPase Activation on Seizure Activity in Acute versus Chronic Models. *Neuroscience* **2015**, *298*, 171–179. [[CrossRef](#)]
88. Krishnan, G.P.; Filatov, G.; Shilnikov, A.; Bazhenov, M. Electrogenic Properties of the Na⁺/K⁺ ATPase Control Transitions between Normal and Pathological Brain States. *J. Neurophysiol.* **2015**, *113*, 3356. [[CrossRef](#)] [[PubMed](#)]
89. Davidson, D.L.W.; Tsukada, Y.; Barbeau, A. Ouabain Induced Seizures: Site of Production and Response to Anticonvulsants. *Can. J. Neurol. Sci.* **1978**, *5*, 405–411. [[CrossRef](#)] [[PubMed](#)]
90. McCarren, M.; Alger, B.E. Sodium-Potassium Pump Inhibitors Increase Neuronal Excitability in the Rat Hippocampal Slice: Role of a Ca²⁺-Dependent Conductance. *J. Neurophysiol.* **1987**, *57*, 496–509. [[CrossRef](#)] [[PubMed](#)]
91. Shao, L.R.; Janicot, R.; Stafstrom, C.E. Na⁺-K⁺-ATPase Functions in the Developing Hippocampus: Regional Differences in CA1 and CA3 Neuronal Excitability and Role in Epileptiform Network Bursting. *J. Neurophysiol.* **2021**, *125*, 1–11. [[CrossRef](#)]
92. Hosseinzadeh, Z.; Hauser, S.; Singh, Y.; Pelzl, L.; Schuster, S.; Sharma, Y.; Höflinger, P.; Zacharopoulou, N.; Stourmaras, C.; Rathbun, D.L.; et al. Decreased Na⁺/K⁺ ATPase Expression and Depolarized Cell Membrane in Neurons Differentiated from Chorea-Acanthocytosis Patients. *Sci. Rep.* **2020**, *10*, 8391. [[CrossRef](#)]
93. Rapport, R.L.; Harris, A.B.; Friel, P.N.; Ojemann, G.A. Human Epileptic Brain Na, K ATPase Activity and Phenytoin Concentrations. *Arch. Neurol.* **1975**, *32*, 549–554. [[CrossRef](#)]
94. Ygberg, S.; Akkuratov, E.E.; Howard, R.J.; Taylan, F.; Jans, D.C.; Mahato, D.R.; Katz, A.; Kinoshita, P.F.; Portal, B.; Nennesmo, I.; et al. A Missense Mutation Converts the Na⁺,K⁺-ATPase into an Ion Channel and Causes Therapy-Resistant Epilepsy. *J. Biol. Chem.* **2021**, *297*, 101355. [[CrossRef](#)]
95. Vetro, A.; Nielsen, H.N.; Holm, R.; Hevner, R.F.; Parrini, E.; Powis, Z.; Møller, R.S.; Bellan, C.; Simonati, A.; Lesca, G.; et al. ATP1A2- and ATP1A3-Associated Early Profound Epileptic Encephalopathy and Polymicrogyria. *Brain* **2021**, *144*, 1435–1450. [[CrossRef](#)]
96. De Fusco, M.; Marconi, R.; Silvestri, L.; Atorino, L.; Rampoldi, L.; Morgante, L.; Ballabio, A.; Aridon, P.; Casari, G. Haploinsufficiency of ATP1A2 Encoding the Na⁺/K⁺ Pump Alpha2 Subunit Associated with Familial Hemiplegic Migraine Type 2. *Nat. Genet.* **2003**, *33*, 192–196. [[CrossRef](#)]
97. Deprez, L.; Weckhuysen, S.; Peeters, K.; Deconinck, T.; Claeys, K.G.; Claes, L.R.F.; Suls, A.; Van Dyck, T.; Palmi, A.; Matthijs, G.; et al. Epilepsy as Part of the Phenotype Associated with ATP1A2 Mutations. *Epilepsia* **2008**, *49*, 500–508. [[CrossRef](#)]
98. Costa, C.; Prontera, P.; Sarchielli, P.; Tonelli, A.; Bassi, M.T.; Cupini, L.M.; Caproni, S.; Siliquini, S.; Donti, E.; Calabresi, P. A Novel ATP1A2 Gene Mutation in Familial Hemiplegic Migraine and Epilepsy. *Cephalalgia* **2014**, *34*, 68–72. [[CrossRef](#)]
99. Segall, L.; Scanzano, R.; Kaunisto, M.A.; Wessman, M.; Palotie, A.; Gargus, J.J.; Blostein, R. Kinetic Alterations Due to a Missense Mutation in the Na,K-ATPase Alpha2 Subunit Cause Familial Hemiplegic Migraine Type 2. *J. Biol. Chem.* **2004**, *279*, 43692–43696. [[CrossRef](#)]
100. Segall, L.; Mezzetti, A.; Scanzano, R.; Gargus, J.J.; Purisima, E.; Blostein, R. Alterations in the Alpha2 Isoform of Na,K-ATPase Associated with Familial Hemiplegic Migraine Type 2. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 11106–11111. [[CrossRef](#)]
101. Vanmolkot, K.R.J.; Stroink, H.; Koenderink, J.B.; Kors, E.E.; Van Den Heuvel, J.J.M.W.; Van Den Boogerd, E.H.; Stam, A.H.; Haan, J.; De Vries, B.B.A.; Terwindt, G.M.; et al. Severe Episodic Neurological Deficits and Permanent Mental Retardation in a Child with a Novel FHM2 ATP1A2 Mutation. *Ann. Neurol.* **2006**, *59*, 310–314. [[CrossRef](#)]
102. Li, Y.; Tang, W.; Kang, L.; Kong, S.; Dong, Z.; Zhao, D.; Liu, R.; Yu, S. Functional Correlation of ATP1A2 Mutations with Phenotypic Spectrum: From Pure Hemiplegic Migraine to Its Variant Forms. *J. Headache Pain* **2021**, *22*, 92. [[CrossRef](#)]
103. Moya-Mendez, M.E.; Mueller, D.M.; Pratt, M.; Bonner, M.; Elliott, C.; Hunanyan, A.; Kucera, G.; Bock, C.; Prange, L.; Jasien, J.; et al. Early Onset Severe ATP1A2 Epileptic Encephalopathy: Clinical Characteristics and Underlying Mutations. *Epilepsy Behav.* **2021**, *116*, 107732. [[CrossRef](#)]
104. Calame, D.G.; Houck, K.; Lotze, T.; Emrick, L.; Parnes, M. A Novel ATP1A2 Variant Associated with Severe Stepwise Regression, Hemiplegia, Epilepsy and Movement Disorders in Two Unrelated Patients. *Eur. J. Paediatr. Neurol.* **2021**, *31*, 21–26. [[CrossRef](#)]

105. Ishii, A.; Saito, Y.; Mitsui, J.; Ishiura, H.; Yoshimura, J.; Arai, H.; Yamashita, S.; Kimura, S.; Oguni, H.; Morishita, S.; et al. Identification of ATP1A3 Mutations by Exome Sequencing as the Cause of Alternating Hemiplegia of Childhood in Japanese Patients. *PLoS ONE* **2013**, *8*, e56120. [[CrossRef](#)]
106. Paciorkowski, A.R.; McDaniel, S.S.; Jansen, L.A.; Tully, H.; Tuttle, E.; Ghoneim, D.H.; Tupal, S.; Gunter, S.A.; Vasta, V.; Zhang, Q.; et al. Novel Mutations in ATP1A3 Associated with Catastrophic Early Life Epilepsy, Episodic Prolonged Apnea, and Postnatal Microcephaly. *Epilepsia* **2015**, *56*, 422–430. [[CrossRef](#)]
107. Kirshenbaum, G.S.; Dawson, N.; Mullins, J.G.L.; Johnston, T.H.; Drinkhill, M.J.; Edwards, I.J.; Fox, S.H.; Pratt, J.A.; Brotchie, J.M.; Roder, J.C.; et al. Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na⁺,K⁺-ATPase A3 Missense Mutant Mice. *PLoS ONE* **2013**, *8*, e60141. [[CrossRef](#)]
108. Clapcote, S.J.; Duffy, S.; Xie, G.; Kirshenbaum, G.; Bechard, A.R.; Schack, V.R.; Petersen, J.; Sinai, L.; Saab, B.J.; Lerch, J.P.; et al. Mutation I810N in the 3 Isoform of Na,K-ATPase Causes Impairments in the Sodium Pump and Hyperexcitability in the CNS. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 14085–14090. [[CrossRef](#)]
109. Azzaz, F.; Yahi, N.; di Scala, C.; Chahinian, H.; Fantini, J. Ganglioside Binding Domains in Proteins: Physiological and Pathological Mechanisms. *Adv. Protein Chem. Struct. Biol.* **2022**, *128*, 289–324. [[CrossRef](#)]
110. Cantu', L.; Corti, M.; Brocca, P.; del Favero, E. Structural Aspects of Ganglioside-Containing Membranes. *Biochim. Biophys. Acta Biomembr.* **2009**, *1788*, 202–208. [[CrossRef](#)]
111. Sandhoff, R.; Schulze, H.; Sandhoff, K. Gangliosides in Health and Disease. In *Progress in Molecular Biology and Translational Science*, 1st ed.; Schnaar, R.L., Lopez, P.H.H., Eds.; Academic Press Inc.: Dordrecht, The Netherlands, 2018; Volume 156, pp. 1–462.
112. Rodriguez, P.E.A.; Maggio, B.; Cumar, F.A. Acid and Enzymatic Hydrolysis of the Internal Sialic Acid Residue in Native and Chemically Modified Ganglioside GM1. *J. Lipid Res.* **1996**, *37*, 382–390. [[CrossRef](#)]
113. Cornelius, F. Cholesterol Modulation of Molecular Activity of Reconstituted Shark Na⁺, K⁽⁺⁾-ATPase. *Biochim. Biophys. Acta Biomembr.* **1995**, *1235*, 205–212. [[CrossRef](#)]
114. Habeck, M.; Haviv, H.; Katz, A.; Kapri-Pardes, E.; Ayciriex, S.; Shevchenko, A.; Ogawa, H.; Toyoshima, C.; Karlish, S.J.D. Stimulation, Inhibition, or Stabilization of Na,K-ATPase Caused by Specific Lipid Interactions at Distinct Sites. *J. Biol. Chem.* **2015**, *290*, 4829–4842. [[CrossRef](#)] [[PubMed](#)]
115. Kanai, R.; Cornelius, F.; Ogawa, H.; Motoyama, K.; Vilsen, B.; Toyoshima, C. Binding of Cardiotonic Steroids to Na⁺,K⁺-ATPase in the E2P State. *Proc. Natl. Acad. Sci. USA* **2020**, *118*, e2020438118. [[CrossRef](#)]
116. Puljko, B.; Stojanović, M.; Ilic, K.; Maček Hrvat, N.; Zovko, A.; Damjanović, V.; Mlinac-Jerkovic, K.; Kalanj-Bognar, S. Redistribution of Gangliosides Accompanies Thermally Induced Na⁺,K⁺-ATPase Activity Alternation and Submembrane Localisation in Mouse Brain. *Biochim. Biophys. Acta Biomembr.* **2021**, *1863*, 183475. [[CrossRef](#)]
117. Vyas, K.A.; Patel, H.V.; Vyas, A.A.; Schnaar, R.L. Segregation of Gangliosides GM1 and GD3 on Cell Membranes, Isolated Membrane Rafts, and Defined Supported Lipid Monolayers. *Biol. Chem.* **2001**, *382*, 241–250. [[CrossRef](#)]
118. Liang, M.; Tian, J.; Liu, L.; Pierre, S.; Liu, J.; Shapiro, J.; Xie, Z.J. Identification of a Pool of Non-Pumping Na/K-ATPase. *J. Biol. Chem.* **2007**, *282*, 10585–10593. [[CrossRef](#)]
119. Liebmann, T.; Fritz, N.; Kruusmägi, M.; Westin, L.; Bernhem, K.; Bondar, A.; Aperia, A.; Brismar, H. Regulation of Neuronal Na,K-ATPase by Extracellular Scaffolding Proteins. *Int. J. Mol. Sci.* **2018**, *19*, 2214. [[CrossRef](#)]
120. Esmann, M.; Marsh, D.; Schwarzmann, G.; Sandhoff, K. Ganglioside-Protein Interactions: Spin-Label Electron Spin Resonance Studies with (Na⁺,K⁺)-ATPase Membranes. *Biochemistry* **1988**, *27*, 2398–2403. [[CrossRef](#)]
121. Jeserich, G.; Breer, H.; Düvel, M. Effect of Exogenous Gangliosides on Synaptosomal Membrane ATPase Activity. *Neurochem. Res.* **1981**, *6*, 465–474. [[CrossRef](#)]
122. Wood, P.A.; McBride, M.R.; Baker, H.J.; Christian, S.T. Fluorescence Polarization Analysis, Lipid Composition, and Na⁺,K⁺-ATPase Kinetics of Synaptosomal Membranes in Feline GM1 and GM2 Gangliosidosis. *J. Neurochem.* **1985**, *44*, 947–956. [[CrossRef](#)]
123. Mirzoyan, S.A.; Mkheyanyan, E.E.; Sekoyan, E.S.; Sotskii, O.P.; Akopov, S.E. Effect of Gangliosides on Na,K-ATPase Activity and Conformation of Microsomal Membranes. *Bull. Exp. Biol. Med.* **1978**, *86*, 1607–1610. [[CrossRef](#)]
124. Caputto, R.; Maccioni, A.H.R.; Caputto, B.L. Activation of Deoxycholate Solubilized Adenosine Triphosphatase by Ganglioside and Asialoganglioside Preparations. *Biochem. Biophys. Res. Commun.* **1977**, *74*, 1046–1052. [[CrossRef](#)]
125. Leon, A.; Facci, L.; Toffano, G.; Sonnino, S.; Tettamanti, G. Activation of (Na⁺,K⁺)-ATPase by Nanomolar Concentrations of GM1 Ganglioside. *J. Neurochem.* **1981**, *37*, 350–357. [[CrossRef](#)]
126. Nagata, Y.; Ando, M.; Hori, S. Stimulative Effect of Nerve Growth Factor on Alpha-Aminoisobutyric Acid Uptake and Na,K-ATPase Activity in Superior Cervical Sympathetic Ganglia Excised from Adult Rats. *Neurochem. Res.* **1985**, *10*, 1173–1185. [[CrossRef](#)]
127. Ando, M.; Nakashima, Y.; Nagata, Y. Effects of GM1-Ganglioside and α-Sialyl Cholesterol on Amino Acid Uptake, Protein Synthesis, and Na⁺,K⁺-ATPase Activity in Superior Cervical and Nodose Ganglia Excised from Adult Rats. *Mol. Chem. Neuropathol.* **1990**, *13*, 33–46. [[CrossRef](#)]
128. Nagata, Y.; Ando, M.; Iwata, M.; Hara, A.; Taketomi, T. Effect of Exogenous Gangliosides on Amino Acid Uptake and Na⁺,K⁺-ATPase Activity in Superior Cervical and Nodose Ganglia of Rats. *J. Neurochem.* **1987**, *49*, 201–207. [[CrossRef](#)]
129. Karpiak, S.E.; Li, Y.S.; Mahadik, S.P. Gangliosides (GM1 and AGF2) Reduce Mortality Due to Ischemia: Protection of Membrane Function. *Stroke* **1987**, *18*, 184–187. [[CrossRef](#)]

130. Mahadik, S.P.; Hawver, D.B.; Hungund, B.L.; Li, Y.S.; Karpiak, S.E. GM1 Ganglioside Treatment after Global Ischemia Protects Changes in Membrane Fatty Acids and Properties of Na⁺,K⁺-ATPase and Mg²⁺-ATPase. *J. Neurosci. Res.* **1989**, *24*, 402–412. [[CrossRef](#)]
131. Lodovici, M.; Dolara, P.; Amerini, S.; Mantelli, L.; Ledda, F.; Bennardini, F.; Fazi, M.; Montereggi, A.; Dini, G. Effects of GM1 Ganglioside on Cardiac Function Following Experimental Hypoxia-Reoxygenation. *Eur. J. Pharmacol.* **1993**, *243*, 255–263. [[CrossRef](#)]
132. Bianchi, R.; Zhu, X.; Fiori, M.G.; Eichberg, J. Effect of Gangliosides on Diacylglycerol Content and Molecular Species in Nerve from Diabetic Rats. *Eur. J. Pharmacol.* **1993**, *239*, 55–61. [[CrossRef](#)]
133. Kreutz, F.; Scherer, E.B.; Ferreira, A.G.K.; Petry, F.D.S.; Pereira, C.L.; Santana, F.; De Souza Wyse, A.T.; Salbego, C.G.; Trindade, V.M.T. Alterations on Na⁺,K⁺-ATPase and Acetylcholinesterase Activities Induced by Amyloid- β Peptide in Rat Brain and GM1 Ganglioside Neuroprotective Action. *Neurochem. Res.* **2013**, *38*, 2342–2350. [[CrossRef](#)]
134. Morth, J.P.; Pedersen, B.P.; Toustrup-Jensen, M.S.; Sørensen, T.L.M.; Petersen, J.; Andersen, J.P.; Vilsen, B.; Nissen, P. Crystal Structure of the Sodium–Potassium Pump. *Nature* **2007**, *450*, 1043–1049. [[CrossRef](#)]
135. Fazzari, M.; Lunghi, G.; Chiricozzi, E.; Mauri, L.; Sonnino, S. Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition. *Biomedicines* **2022**, *10*, 363. [[CrossRef](#)]
136. Mancini, G.; Loberto, N.; Oliosio, D.; Dehecchi, M.C.; Cabrini, G.; Mauri, L.; Bassi, R.; Schiumarini, D.; Chiricozzi, E.; Lippi, G.; et al. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. *Int. J. Mol. Sci.* **2020**, *21*, 4486. [[CrossRef](#)]